Remote Cardiac Rehabilitation for Congenital Heart Disease
(Remote-CaRe Trial)
Trial Summary
What is the purpose of this trial?
The goal of this randomized controlled trial is to evaluate the effectiveness of video conferencing for the delivery of live-supervised, real-time cardiac rehabilitation (CR) exercise training to groups of adolescents with congenital heart disease (CHD) in their homes. Participants will be randomized to either the remote cardiac rehab (RCR) group or active control group. The RCR group will participate in live, group-based exercise training (3-5 participants per exercise session), in their homes 3 days per week for 45 minutes over 12-weeks. Exercise sessions will be led and supervised by a live health coach via telehealth video technology. The active control group will be provided informational handouts on health exercise for their cardiac diagnosis. The primary aim is to compare between group changes (0-12-weeks) in cardiorespiratory fitness (VO2peak). Secondary aims are to compare between group changes (0-12-weeks) in cardiac function (echocardiography), lean body mass, and physical frailty. Exploratory aims will compare between group changes (0-12-weeks) in physical function, quality of life, skeletal muscle function, and physical activity self-efficacy. Additionally, exploratory aims will explore the impact of demographic characteristics, program participation, program satisfaction, and daily physical activity on changes in cardiorespiratory fitness.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude participants who are prescribed milrinone. If you are taking this medication, you would not be eligible to participate.
What data supports the effectiveness of the treatment Remote Cardiac Rehabilitation for Congenital Heart Disease?
Research shows that remote cardiac rehabilitation, which includes exercise and digital support, is as effective as in-person programs for improving health outcomes in heart patients. It helps increase physical activity and quality of life, and can be especially beneficial for those who face barriers to attending traditional rehab programs.12345
Is remote cardiac rehabilitation safe for humans?
How is the Remote Cardiac Rehabilitation treatment for Congenital Heart Disease different from other treatments?
Remote Cardiac Rehabilitation is unique because it allows patients to participate in cardiac rehab from home using telemedicine, which can be more convenient and accessible than traditional in-person programs. This approach is particularly beneficial during situations like the COVID-19 pandemic, where attending in-person sessions may be challenging.110111213
Research Team
David A White, PhD
Principal Investigator
Children's Mercy Kansas City
Eligibility Criteria
Adolescents aged 12-19 with specific congenital heart diseases, internet access at home, and cleared for exercise by their cardiologist. They must be available for in-home exercises during weekdays and not have conditions like uncontrolled asthma or reliance on a pacemaker.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Ramp-up
Participants engage in a 2-week ramp-up period with live health coach sessions
Treatment
Participants receive live-supervised, group-based exercise training via telehealth
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Monitoring
Participants are encouraged to wear a physical activity monitor for a minimum of 6 months
Treatment Details
Interventions
- Active Control
- Remote Cardiac Rehab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Mercy Hospital Kansas City
Lead Sponsor
Children's Hospital of Philadelphia
Collaborator
University of North Carolina, Chapel Hill
Collaborator
University of Kansas
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator